Official Title
The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health
Brief Title
Chinese Regional Spinal Muscular Atrophy Patient Registration Study
Protocol ID
NCT05631418
Lead Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Brief Summary
The primary objectives of this study are to obtain clinically meaningful data on the
survival, outcomes, prognosis and treatment effect of all the patients with spinal
muscular atrophy (SMA) 5q types 1 to 3 (according to international classification), being
followed in the Children's Hospital, Zhejiang University School of Medicine since October
2019. The registry will collect retrospectively and prospectively the longitudinal data
of the long-term follow-up for children patients, under real life conditions of current
medical practice, in order to document the clinical evolution of patients (survival,
motor, respiratory, orthopedic and nutritional and so on), the conditions of use of the
treatments, the mortality rates of treated and untreated patients, the tolerance of the
treatments, adverse events.
Detailed Description
The detailed objectives of this study included but not be limited to the following
aspects:
1. to collect and describe overall demographic, familial, clinical, biological, and
genetic characteristics of patients with 5qSMA diagnosed and treated in regions of
China, by the type of SMA (type 1,2, and 3);
2. to study the impact of proactive and symptomatic medical interventions (such as
bracing) and medications (disease-modifying treatment, anti-infectious, digestive,
nutritional supplements, ect.) in the evolution of patients;
3. to study the long-term evolution (survival, motor and respiratory functions, spinal
shape, growth and nutritional function) of 5qSMA in treated and untreated
populations, by new available therapies;
4. to study the incidence and mortality rate of 5qSMA in treated and untreated
populations;
5. to identify and document the different therapeutic strategies by sub-populations and
by discontinuation or follow-up of treatments;
6. to evaluate prognostic factors of responses to different drug therapies;
7. to study the tolerance of treatments by type of treatments, by type of SMA and
overall tolerance (including adverse events);
8. to help popularize newborn screening for SMA and pre-symptom treatment among Chinese
population;
9. to get knowledge of the probable costs of care for 5qSMA patients in different
groups (disease types, ages);
10. to provide needful elements to evaluate the health care costs for the disease;
11. to study the autonomy and the quality of life of patients depending on different
therapies and the impact on patients' caregivers;
12. to help facilitate development of basic research on SMA in the conduct of trials on
new treatment.
Enrollment Count
0 participants
Eligibility Criteria
Inclusion Criteria:
1. Genetically confirmed 5qSMA patients through 1 to 3 types younger than 18 years old
followed in our hospital since October 2019;
2. For prospective study: inform consent form signed by patient;
3. Not combined with any other genetic and metabolic diseases;
Exclusion Criteria:
1. Other type of SMA (not 5q).
2. Under guardianship or curatorship.
3. Unable to understand or cooperate with the study.
Filters
Recruitment
WITHDRAWN
CHILD
ADULT